Home › Merck Statement regarding Role of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
 

Keywords :   


Merck Statement regarding Role of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults

2014-08-13 23:58:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIPs) updated pneumococcal vaccine recommendations for adults 65 years of age and older. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in updated statement role

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Weekly Recap: Ontex Enters Agreement to Sell Brazilian Business, Winner Acquires Stake in GRI ...
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Public Advisory Number 4A
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Atlantic Tropical Weather Outlook
06.10Eastern North Pacific Tropical Weather Outlook
06.10Ex-cabinet secretary says 200,000 job is underpaid
06.10Hurricane Leslie Graphics
More »